FI903292A0 - T-cellepitop som baerarmolekyler foer konjugerade vacciner. - Google Patents

T-cellepitop som baerarmolekyler foer konjugerade vacciner.

Info

Publication number
FI903292A0
FI903292A0 FI903292A FI903292A FI903292A0 FI 903292 A0 FI903292 A0 FI 903292A0 FI 903292 A FI903292 A FI 903292A FI 903292 A FI903292 A FI 903292A FI 903292 A0 FI903292 A0 FI 903292A0
Authority
FI
Finland
Prior art keywords
vacciner
kjjugerade
cellepitop
baerarmolekyler
som
Prior art date
Application number
FI903292A
Other languages
English (en)
Other versions
FI104374B (fi
Inventor
Garvin Bixler
Subramonia Pillai
Richard Insel
Original Assignee
Praxis Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc filed Critical Praxis Biolog Inc
Publication of FI903292A0 publication Critical patent/FI903292A0/fi
Application granted granted Critical
Publication of FI104374B publication Critical patent/FI104374B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Optical Couplings Of Light Guides (AREA)
FI903292A 1988-02-01 1990-06-29 T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus FI104374B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15068888A 1988-02-01 1988-02-01
US15068888 1988-02-01
PCT/US1989/000388 WO1989006974A2 (en) 1988-02-01 1989-01-31 T-cell epitope as carriers molecule for conjugate vaccines
US8900388 1989-01-31

Publications (2)

Publication Number Publication Date
FI903292A0 true FI903292A0 (fi) 1990-06-29
FI104374B FI104374B (fi) 2000-01-14

Family

ID=22535596

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903292A FI104374B (fi) 1988-02-01 1990-06-29 T-solu-epitooppi-oligopeptidejä ja niitä sisältävien konjugaattien valmistus

Country Status (10)

Country Link
EP (1) EP0399001B1 (fi)
JP (1) JP2921574B2 (fi)
AT (1) ATE109008T1 (fi)
AU (1) AU634153B2 (fi)
CA (2) CA1340958C (fi)
DE (1) DE68917126T2 (fi)
DK (1) DK174416B1 (fi)
FI (1) FI104374B (fi)
NO (1) NO179164C (fi)
WO (1) WO1989006974A2 (fi)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497883B1 (en) * 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
DE4192335T1 (de) * 1990-09-18 1993-10-07 Biotech Australia Pty Ltd T-Zell-Epitope
WO1993011157A1 (en) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX)
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
AU4580093A (en) * 1992-07-22 1994-02-14 Proteus Molecular Design Limited Polypeptide antigens of mycobacterium bovis
DK0652962T3 (da) * 1992-07-31 1999-08-23 Medeva Holdings Bv Ekspression af rekombinante fusionsproteiner i attenuerede bakterier
KR950702839A (ko) 1992-08-27 1995-08-23 스티븐 딕 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues)
DK140992D0 (da) * 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
JPH09500540A (ja) * 1993-07-30 1997-01-21 メデヴァ ホールディングス ビー．ヴイ． ワクチン組成物
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
AU1864195A (en) * 1994-03-07 1995-09-25 Auckland Uniservices Limited Prevention of diabetes
US5773003A (en) * 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
AU5374996A (en) * 1995-03-31 1996-10-16 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
EP0895538B1 (en) 1996-04-19 2002-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
DE19856052A1 (de) * 1998-12-04 2000-06-08 Deutsches Krebsforsch Konjugat zur Anreicherung in neuronalen Zellen
US6663861B2 (en) 2000-11-09 2003-12-16 Antibodyshop A/S Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
KR20110084906A (ko) 2008-10-10 2011-07-26 에라 바이오테크, 에스.에이. 면역원-특이적 면역보강제로서의 재조합 단백질체들
EP2411039A4 (en) * 2009-03-23 2015-05-06 Brigham & Womens Hospital Glycoconjugate VACCINES
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3562503A2 (en) 2016-12-30 2019-11-06 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN112543649A (zh) 2018-07-04 2021-03-23 Vaxcyte公司 免疫原性缀合物的改进
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates

Also Published As

Publication number Publication date
DK174416B1 (da) 2003-02-17
WO1989006974A2 (en) 1989-08-10
CA1340958C (en) 2000-04-11
DK182990D0 (da) 1990-07-31
DE68917126T2 (de) 1995-02-02
WO1989006974A3 (en) 1989-08-24
CA1340956C (en) 2000-04-11
EP0399001A1 (en) 1990-11-28
AU3065489A (en) 1989-08-25
EP0399001B1 (en) 1994-07-27
NO179164B (no) 1996-05-13
JP2921574B2 (ja) 1999-07-19
ATE109008T1 (de) 1994-08-15
AU634153B2 (en) 1993-02-18
JPH03502691A (ja) 1991-06-20
FI104374B (fi) 2000-01-14
DK182990A (da) 1990-07-31
NO902909D0 (no) 1990-06-29
DE68917126D1 (de) 1994-09-01
NO179164C (no) 1996-08-21
NO902909L (no) 1990-08-27

Similar Documents

Publication Publication Date Title
FI903292A0 (fi) T-cellepitop som baerarmolekyler foer konjugerade vacciner.
DK1089760T3 (da) Kunstige T-hjælpecelleepitoper som immunstimulatorer for syntetiske peptidimmunogener
RU95105991A (ru) Конъюгат, вакцина, способы усиления иммуногенности, способы иммунизации
DE3380053D1 (en) Conjugates of haptenes and muramyl peptides having an immunogenic activity, and compositions containing them
NO974727L (no) Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
DE69333402D1 (en) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
AU7547987A (en) Method of preparation and use for feline leukemia virus antigens
CO5241277A1 (es) Vacuna
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
FG Patent granted

Owner name: WYETH HOLDINGS CORPORATION

MA Patent expired